What did @nataliejillfit actually say?
The claim is that hormone replacement therapy was standard care through the 80s and 90s, then pulled overnight after the Women's Health Initiative (WHI) flagged breast cancer and cardiovascular risks, that those findings didn't hold up on reanalysis, and that the resulting research gap left women without good evidence for 22 to 23 years. She also notes estrogen therapy has been prescribed since 1942 and that 30 to 70 percent of perimenopausal and menopausal women received HRT during peak prescribing years.
That is a lot of ground to cover in a short clip, and some of it lands, some of it oversimplifies, and at least one part needs a significant asterisk.
Does the science back this up?
Partially, yes. The broad historical arc she describes is accurate enough. HRT prescribing did drop sharply after the WHI published in 2002. Rossouw et al. (2002, JAMA) reported increased risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism in women taking combined estrogen-progestin. Prescriptions fell by roughly 50 percent within two years in the United States.
The reanalysis argument has real merit. Subsequent work, including the landmark "timing hypothesis" research by Manson et al. (2013, JAMA Internal Medicine) and Hodis et al. (2016, NEJM), showed that women who started HRT close to menopause onset did not carry the same cardiovascular risks as the older, predominantly post-menopausal women in the original WHI cohort. The WHI population had a mean age of 63, which is not representative of women typically prescribed HRT today.
The 30 to 70 percent prescribing estimate is plausible but wide enough to be almost unfalsifiable. Country-specific data from the UK and US does support high prescribing rates in the early 1990s, though the top end of 70 percent is hard to pin to a single source.
What did they get wrong (or right)?
The phrase "none of which followed through on the data" is where things get sloppy. The original WHI findings were not simply fabricated or later fully disproven. The combined estrogen-progestin arm did show a statistically significant increase in invasive breast cancer (hazard ratio 1.26, Rossouw et al., 2002, JAMA). That signal has not disappeared. What subsequent research clarified is that risk varies substantially by hormone type, formulation, timing of initiation, and patient age. Estrogen-only therapy in women who had hysterectomies actually showed a reduced breast cancer risk in longer follow-up (Anderson et al., 2012, Lancet Oncology).
So the correct statement is not that the original risks were wrong, it is that the original study was applied too broadly to a population it did not represent. That is a meaningful distinction she glosses over.
The 1942 FDA approval of Premarin is accurate. And her point about a research gap in women's midlife health is well supported. The NAMS 2022 position statement explicitly acknowledges that evidence gaps remain, particularly for longer-term HRT use and for specific subpopulations.
What should you actually know?
The story of HRT and the WHI is genuinely one of the more consequential overcorrections in modern medicine. Real women were taken off therapy that was helping them based on findings that were later shown to apply poorly to younger, recently menopausal patients. The North American Menopause Society, the British Menopause Society, and the Endocrine Society have all updated guidelines since 2015 to reflect that for healthy women under 60 or within 10 years of menopause onset, the benefit-risk profile for HRT is generally favorable for symptom management.
But the nuance matters. Breast cancer risk with combined estrogen-progestin HRT is a real, if modest, concern that has not been fully erased by reanalysis. Women with specific risk profiles, including BRCA mutations, prior hormone-sensitive cancers, or certain cardiovascular histories, need individualized assessment. A blanket "it was all wrong" framing does not serve those patients well.
The research gap argument is legitimate. A 2020 analysis in Menopause (Kaunitz and Manson) documented that funding for women's midlife health research lagged significantly after 2002, and that clinical training in menopause medicine became sparse. She is right that the ripple effects are still being felt.